Диффузная срединная глиома ствола головного мозга: генетические особенности, сложности и перспективы лечения

Диффузная срединная глиома головного мозга - редкая, но очень агрессивная и резистентная глиальная опухоль. Данная патология характеризуется невозможностью выполнения радикального хирургического лечения, радиорезистентностью, невосприимчивостью к лекарственной терапии, высокой детской заболеваемостью, низким качеством жизни пациентов, частым развитием осложнений в виде неврологического дефицита и неблагоприятным прогнозом. Отсутствие эффективной схемы лечения диффузной срединной глиомы головного мозга вызывает необходимость поиска альтернативных методов (терапия вирусами, иммунотерапия), однако данных по этой теме пока недостаточно, что требует ее дальнейшего изучения.

1. Hargrave D., Bartels U., Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 2006;7(3):241-8. DOI: 10.1016/S1470-2045(06)70615-5

2. Hennika T., Becher O.J. Diffuse Intrinsic pontine glioma: time for cautious optimism. J Child Neurol 2016;31(12):1377—85. DOI: 10.1177/0883073815601495

3. Schroeder K.M., Hoeman C.M., Becher O.J. Children are not just little adults: recent advances in understanding of diffuse intrinsic pontine glioma biology. Pediatr Res 2014;75(1-2):205-9. DOI: 10.1038/pr.2013.194

4. Tinkle C.L., Duncan E.C., Doubrovin M. et al. Evaluation of 11C-methionine PET and anatomic MRI associations in diffuse intrinsic pontine glioma. J Nucl Med 2019;60(3):312-9. DOI: 10.2967/jnumed.118.212514

5. Kossatz S., Carney B., Schweitzer M. et al. Biomarker-based PET imaging of diffuse Intrinsic pontine glioma in mouse models. Cancer Res 2017;77(8):2112-23. DOI: 10.1158/0008-5472.CAN-16-2850

6. Grimm S.A., Chamberlain M.C. Brainstem glioma: a review. Curr Neurol Neurosci Rep 2013;13(5):346. DOI: 10.1007/s11910-013-0346-3

7. Pollack I.F., Agnihotri S., Broniscer A. Childhood brain tumors: current management, biological insights, and future directions. J Neurosurg Pediatr 2019;23(3):261-73. DOI: 10.3171/2018.10.PEDS18377

8. Liu I., Jiang L., Samuelsson E.R. et al. The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location. Nat Genet 2022;54(12):1881-94. DOI: 10.1038/s41588-022-01236-3

9. Gwak H.-S., Park H.J. Developing chemotherapy for diffuse pontine intrinsic gliomas (DIPG). Crit Rev Oncol Hematol 2017;120:111-9. DOI: 10.1016/j.critrevonc.2017.10.013

10. Hoffman L.M., Veldhuijzen van Zanten S.E.M., Colditz N. et al. Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of diffuse intrinsic pontine glioma (DIPG): a collaborative report from the International and European Society for Pediatric Oncology DIPG registries. J Clin Oncol 2018;36(19):1963-72. DOI: 10.1200/JCO.2017.75.9308

11. Miguel Llordes G., Medina Perez V.M., Curto Simon B. et al. Epidemiology, diagnostic strategies, and therapeutic advances in diffuse midline glioma. J Clin Med 2023;12(16):5261. DOI: 10.3390/jcm12165261

12. Gerstner E.R. MRI and PET: noninvasive tools to probe the biology of diffuse intrinsic pontine glioma. J Nucl Med 2017;8(8):1262-3. DOI: 10.2967/jnumed.117.192526

13. Perrone M.G., Ruggiero A., Centonze A. et al. Diffuse intrinsic pontine glioma (DIPG): breakthrough and clinical perspective. Curr Med Chem 2021;28(17):3287-317. DOI: 10.2174/0929867327666200806110206

14. Robison N.J., Kieran M.W. Diffuse intrinsic pontine glioma: a reassessment. J Neurooncol 2014;119(1):7-15. DOI: 10.1007/s11060-014-1448-8

15. Mackay A., Burford A., Carvalho D. et al. Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell 2017;32(4):520-37.e5. DOI: 10.1016/j.ccell.2017.08.017

16. Yu J.-R., LeRoy G., Bready D. et al. The H3K36me2 writer-reader dependency in H3K27M-DIPG Sci Adv 2021;7(9):eabg7444. DOI: 10.1126/sciadv.abg7444

17. Buczkowicz P., Hoeman C., Rakopoulos P. et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet 2014;46(5):451-6. DOI: 10.1038/ng.2936

18. Majzner R.G., Ramakrishna S., Yeom K.W. et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 2022;603(7903):934-41. DOI: 10.1038/s41586-022-04489-4

19. Kurdi N., Mokanszki A., Mehes G., Bedekovics J. Histone H3 K27 alterations in central nervous system tumours: challenges and alternative diagnostic approaches. Mol Cell Probes 2022;66:101876. DOI: 10.1016/j.mcp.2022.101876

20. Wu G., Diaz A.K., Paugh B.S. et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet 2014;46(5):444-50. DOI: 10.1038/ng.2938

21. Chi A.S., Tarapore R.S., Hall M.D. et al. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. J Neurooncol 2019;145(1):97-105. DOI: 10.1007/s11060-019-03271-3

22. Carai A., Marcus H.J., Tisdall M., Aquilina K. Robot-assisted stereotactic biopsy of diffuse Intrinsic pontine glioma: a single-center experience.World Neurosurg 2017;101:584-8. DOI: 10.1016/j.wneu.2017.02.088

23. Morana G., Tortora D., Bottoni G. et al. Correlation of multimodal 18F-DOPA PET and conventional MRI with treatment response and survival in children with diffuse intrinsic pontine gliomas. Theranostics 2020;10(26):11881-91. DOI: 10.7150/thno.50598

24. Wang Z.J., Rao L., Bhambhani K. et al. Diffuse intrinsic pontine glioma biopsy: a single institution experience. Pediatr Blood Cancer 2015;62(1):163-5. DOI: 10.1002/pbc.25224

25. Rashed W.M., Maher E., Adel M. et al. Pediatric diffuse intrinsic pontine glioma: where do we stand? Cancer Metastasis Rev 2019;38(4):759-70. DOI: 10.1007/s10555-019-09824-2

26. Baker S.J., Ellison D.W., Gutmann D.H. Pediatric gliomas as neurodevelopmental disorders. Glia 2016;64(6):879-95. DOI: 10.1002/glia.22945

27. Hu X., Fang Y., Hui X. et al. Radiotherapy for diffuse brainstem glioma in children and young adults. Cochrane Database Syst Rev 2016;2016(6):CD010439. DOI: 10.1002/14651858.CD010439.pub2

28. Kim H.J., Suh C.-O. Radiotherapy for diffuse intrinsic pontine glioma: insufficient but indispensable. Brain Tumor Res Treat 2023;11(2):79-85. DOI: 10.14791/btrt.2022.0041

29. Reyes-Botero G., Laigle-Donadey F., Mokhtari K. et al. Temozolomide after radiotherapy in recurrent „low grade“ diffuse brainstem glioma in adults. J Neurooncol 2014;120(3):581-6. DOI: 10.1007/s11060-014-1589-9

30. Rizzo D., Scalzone M., Ruggiero A. et al. Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise? J Chemother 2015;27(2):106-10. DOI: 10.1179/1973947814Y.0000000228

31. Wierzbicki K., Ravi K., Franson A. et al. Targeting and therapeutic monitoring of H3K27M-mutant glioma. Curr Oncol Rep 2020;22(2):19. DOI: 10.1007/s11912-020-0877-0

32. Розанов И.Д., Лебедев С.С., Греков и др. Лекарственная терапия глиобластомы головного мозга. Онкология. Журнал им. П.А. Герцена 2023;12(5):65-70. DOI: 10.17116/onkolog20231205165

33. Warren K.E. Beyond the blood: brain barrier: the importance of central nervous system (CNS) pharmacokinetics for the treatment of CNS tumors, including diffuse intrinsic pontine glioma. Front Oncol 2018;8:239. DOI: 10.3389/fonc.2018.00239

34. Carvalho D.M., Richardson P.J., Olaciregui N. et al. Repurposing vandetanib plus everolimus for the treatment of ACVR1-mutant diffuse intrinsic pontine glioma. Cancer Discov 2022;12(2):416-31. DOI: 10.1158/2159-8290.CD-20-1201

35. Gardner S.L., Tarapore R.S., Allen J. et al. Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy. Neurooncol Adv 2022;4(1):vdac143. DOI: 10.1093/noajnl/vdac143

36. Flannery P.C., DeSisto J.A., Amani V. et al. Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma. Oncol Rep 2018;39(2):455-64. DOI: 10.3892/or.2017.6122

37. Gállego Pérez-Larraya J., Garcia-Moure M., Labiano S.P. et al. Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma. N Engl J Med 2022;386(26):2471-81. DOI: 10.1056/NEJMoa2202028

38. Josupeit R., Bender S., Kern S. et al. Pediatric and Adult high-grade glioma stem cell culture models are permissive to lytic infection with parvovirus H-1. Viruses 2016;8(5):138. DOI: 10.3390/v8050138

39. Chastkofsky M.I., Pituch K.C., Katagi H. et al. Mesenchymal stem cells successfully deliver oncolytic virotherapy to diffuse intrinsic pontine glioma. Clin Cancer Res 2021;27(6):1766-77. DOI: 10.1158/1078-0432.CCR-20-1499